In Brief: Idec Rituxan
Idec Rituxan: Company to supply FDA with manufacturing data regarding its anti-CD20 monoclonal antibody rituximab following receipt of Aug. 28 "not approvable" letter. Idec said, however, that FDA has found its clinical data package for non-Hodgkin's lymphoma to be sufficient to support licensure. FDA is requesting additional data regarding Rituxan's process validation and issues stemming from a May inspection of Idec's San Diego manufacturing facility. Company expects to submit the data within 60 days and anticipates approval by year end...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth